ARIA's alk inhibitor has good pharmokinetics so the QD schedule might have an edge over PFE's, but PFE's alk inhibitor might be more effective since it also inhibits cMet. Assume they have same efficacy and safety profile, ARIA's drug is behind PFE by more than 2 years. Is there known cases where a drug with equal efficacy but taken QD took over the market of a drug taken BID?
Market Data 
Markets 
AI
